JOHN H. GLICK, M.D.; ANASTASIOS TSIATIS, Ph.D.
This content is PDF only. Please click on the PDF icon to access.
In the past 2 decades, the prognosis of patients with advanced Hodgkin's disease has improved dramatically because of the development of curative combination chemotherapy. The MOPP regimen (mechlorethamine, vincristine, procarbazine, prednisone) represents the standard against which all alternative chemotherapy or combined modality programs must be judged. The landmark studies of DeVita and colleagues (1) have shown that more than 50% of patients with advanced Hodgkin's disease are cured with chemotherapy alone. Subsequent studies, both by single institutions and cooperative groups, have confirmed the effectiveness of MOPP chemotherapy (2, 3). The importance of administering full doses of MOPP in a timely
GLICK JH, TSIATIS A. MOPP/ABVD Chemotherapy for Advanced Hodgkin's Disease. Ann Intern Med. 1986;104:876–878. doi: 10.7326/0003-4819-104-6-876
Download citation file:
Published: Ann Intern Med. 1986;104(6):876-878.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use